Bristol-myers Squibb Compnay

Wyeth Holdings Corporation

Wyeth

Asana Biosciences, LLC

Nitin Krishnaji Damle

Jeffrey A Ledbetter

Peter S Linsley

William Brady

Arthur Kunz

Mark Edward Ruppen

Justin Keith Moran

Andrew George Popplewell

John W Simpson

Joseph Thomas Rubino

John Francis DiJoseph

Peter A Kiener

Nishith Merchant

Eugene Joseph Vidunas

Neera Jain

Paul David Robbins

Lioudmila Tchistiakova

Davinder Gill

Kimberly Ann Marquette

Erwin R Boghaert

Kiran Khandke

Philip Ross Hamann

Philip M Wallace

Roger Astbury Smith

Timothy B Lowinger

Aleksandr V Yurkovetskiy

Cheri A Stevenson

Alejandro A Aruffo

Mao Yin

Joshua D Thomas

Venu Reddy Gurijala

Kodangattil R Sreekumar

Robert Peach

Jurgen Bajorath

H Perry Fell

Sreekumar R Kodangattil

John McLean Simpson

Robert J Peach

Kodangattil Raman Sreekumar

Lioudmile Tchistiakova

Arthur Kuntz

A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.

Protein-polymer-drug conjugates

Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.

Anti-5T4 antibodies and uses thereof

Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.

Calicheamicin derivative-carrier conjugates

The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.

Soluble CTLA4 mutant molecules

Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions

The present invention provides soluble CTLA4 mutant molecules which bind CD80 and/or CD86 antigen.

Soluble CTLA4 mutant molecules and uses thereof

The invention identifies the B7 antigen as a ligand that is reactive with the CD28 receptor on T cells. The invention further provides methods for using antibodies to B7, or fragments thereof, to regulate CD28 positive T cell response and immune responses mediated by T cells.

Methods for blocking binding of CD28 receptor to B7

This invention provides methods for regulating T cell interactions with B7 positive cells. Methods are provided for using B7 antigen, its fragments and derivatives reactive with CTLA4 receptor, to regulate CTLA4 positive T cell responses, and immune responses mediated by T cells.

Method to inhibit T cell interactions with soluble B7

The invention provides a method for generating and identifying antibodies directed against a B7 antigen having SEQ ID NO. 8 or a fragment of SEQ ID NO. 8, which antibodies inhibit B cells from binding CD28, comprising immunizing an animal with the B7 antigen so as to produce the antibodies; and screening the antibodies for antibodies that bind B7 and inhibit CD28 binding to B cells.

Method for generating and identifying antibodies directed against a B7

Growing community of inventors

Upper Saddle River, NJ, United States of America

Nitin Krishnaji Damle